Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
REPL Replimune
28.290-0.800-2.75%
Close
02/03 16:00 ET
High
29.470
Open
28.490
Turnover
6.63M
Low
26.264
Pre Close
29.090
Volume
232.87K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Sign in to post a comment
$Oncorus(ONCR.US$
The reason why I am interested in oncolytic virus is that the virus itself is a kind of drug, and at the same time, the virus can become the carrier of other drugs. This dual property is not possessed by other drugs at present, and it is up to us to fully exploit this function.$Replimune(REPL.US$$Candel Therapeutics(CADL.US$
The reason why I am interested in oncolytic virus is that the virus itself is a kind of drug, and at the same time, the virus can become the carrier of other drugs. This dual property is not possessed by other drugs at present, and it is up to us to fully exploit this function.$Replimune(REPL.US$$Candel Therapeutics(CADL.US$
Like
Comment
Share
No comment yet
Company Overview
More
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin A. Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
CEO： Mr. Philip Astley-Sparke
Market： NASDAQ
Listing Date： 07/20/2018
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet